Ovid Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ovid Therapeutics (OVID).

Price Target Range — 11 Quarters

Analyst Consensus — 11 Analysts

10Buy

1Hold

Consensus RatingOutperform# Analysts11Avg. Consensus PT$5Upside to Avg. PT+96.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	Cantor Fitzgerald	Imogen Mansfield	Initiate	Overweight	—
Oct 6, 2026	Guggenheim	Delma Caiati	Initiate	Buy	$7
Oct 5, 2026	Guggenheim	Delma Caiati	Initiate	Buy	$7
Sep 11, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$4→$5
Aug 3, 2026	Oppenheimer	Kostas Biliouris	PT Raise	Outperform	$7→$9
Apr 15, 2026	Wedbush	Laura Chico	Maintained	Outperform	$7
Apr 9, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$2→$4
Mar 26, 2026	BTIG	Thomas Shrader	Maintained	Buy	$4
Mar 20, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$5→$7
Dec 22, 2025	LifeSci Capital	—	Initiate	Outperform	$4
Dec 22, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$2
Dec 11, 2025	Roth Capital	Boobalan Pachaiyappan	Initiate	Buy	$3
Nov 24, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$2→$2
Nov 17, 2025	Leerink Partners	Marc Goodman	Initiate	Outperform	$5
May 27, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$2→$2
Mar 24, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$3→$2
Mar 24, 2025	BTIG	Thomas Shrader	PT Cut	Buy	$5→$4
Mar 12, 2025	Wedbush	Laura Chico	PT Cut	Outperform	$4→$3
Jan 29, 2025	Oppenheimer	Francois Brisebois	Upgrade	Perform→Outperform	$4
Dec 4, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$3

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight rating.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $4 to $5.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

Wedbush analyst Laura Chico reiterates Ovid Therapeutics (NASDAQ:OVID) with a Outperform and maintains $7 price target.

Benzinga Newsdesk

Ovid Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Ovid Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PRO
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5

PRO
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

PRO
Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

People Also Watch

People Also Watch

Ovid Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Ovid Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating

PROGuggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PROGuggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PROHC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5

PROOppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

PROWedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

People Also Watch

People Also Watch

PRO
Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PRO
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5

PRO
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

PRO
Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target